Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Inspection Improvements Could Help Fight Drug Shortages, Hospital Group Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Senators also have requested a GAO study of the nature of drug shortages and FDA's ability to respond to them.

You may also be interested in...



Drug Shortage Senate Draft: FDA Told To Look For Impact Before Leaping Into Enforcement

Proposal would require shortage consideration before FDA issues an enforcement action, which could ensure enforcement and shortage staff continue talking.

Rx Shortages Defy Easy Solutions, FDA Notes As It Offers Congress Some Ideas

FDA takes a variety of approaches as it tackles the problem of drug shortages and is tying the high-profile issue to related priorities.

Rx Shortages Defy Easy Solutions, FDA Notes As It Offers Congress Some Ideas

FDA takes a variety of approaches as it tackles the problem of drug shortages and is tying the high-profile issue to related priorities.

Related Content

Topics

UsernamePublicRestriction

Register

PS072647

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel